Amphix Bio

Executive Summary

Amphix Bio is a preclinical-stage biotechnology company pioneering a novel platform technology, Supramolecular Therapeutic Peptides (STPs), designed to modulate immune responses and drive tissue regeneration. Based in Cambridge, MA, the company aims to address unmet needs in injury, disease, and aging by creating therapies that simultaneously trigger targeted signaling pathways and form supportive scaffolds for biological repair. Founded in 2021, Amphix Bio is currently advancing its lead candidates through Phase 1 readiness, focusing on increasing human healthspan. The STP platform offers a differentiated approach by combining immunomodulation with regenerative scaffolding, potentially enabling safer and more effective treatments for chronic indications where traditional biologics fall short. While still in early stages, the company's innovative platform and focus on regenerative medicine position it within a high-growth area of biotech.

Upcoming Catalysts (preview)

• 2026IND Filing for Lead STP Candidate40% success
• Q3 2026Publication of Preclinical Data in Peer-Reviewed Journal70% success
• 2026Series A Financing Announcement50% success